Fluoxetine: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
{{DrugProjectFormSinglePage
{{Fluoxetine}}
|authorTag=
{{CMG}}; {{AE}} {{PB}}


'''''For patient information about Fluoxetine, click [[Fluoxetine (patient information)|here]].'''''


{{SB}} Fluoxetinum<sup>®</sup>, Fluoxetine Hydrochloride<sup>®</sup>, Fluoxetine Hcl<sup>®</sup>, Fluoxetina<sup>®</sup>, Fluoxetina<sup>®</sup>, Animex-On<sup>®</sup>, Deprex<sup>®</sup>, Eufor<sup>®</sup>, Fluctin<sup>®</sup>, Fluoxeren<sup>®</sup>, Fluval<sup>®</sup>, Fontex<sup>®</sup>, Foxetin<sup>®</sup>, Portal<sup>®</sup>, Prozac<sup>®</sup>, Prozac Weekly<sup>®</sup>, Pulvules<sup>®</sup>, Reneuron<sup>®</sup>, Sarafem<sup>®</sup>, Adofen<sup>®</sup>
<!--Overview-->


|genericName=


==Overview==


==Category==


==FDA Package Insert==
|aOrAn=


==FLUOXETINE (fluoxetine hydrochloride) solution==
a


'''  [[FLUOXETINE (fluoxetine hydrochloride) solution indications and usage|Indications and Usage]]'''
|drugClass=
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution dosage and administration|Dosage and Administration]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution contraindications|Contraindications]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution warnings and precautions|Warnings and Precautions]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution adverse reactions|Adverse Reactions]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution drug interactions|Drug Interactions]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution use in specific populations|Use in Specific Populations]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution overdosage|Overdosage]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution description|Description]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution clinical pharmacology|Clinical Pharmacology]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution clinical studies|Clinical Studies]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution patient counseling information|Patient Counseling Information]]'''
'''| [[FLUOXETINE (fluoxetine hydrochloride) solution labels and packages|Labels and Packages]]'''


==PROZAC (fluoxetine hydrochloride) capsule==


'''  [[PROZAC (fluoxetine hydrochloride) capsule indications and usage|Indications and Usage]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule dosage and administration|Dosage and Administration]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule contraindications|Contraindications]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule warnings and precautions|Warnings and Precautions]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule adverse reactions|Adverse Reactions]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule drug interactions|Drug Interactions]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule use in specific populations|Use in Specific Populations]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule overdosage|Overdosage]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule description|Description]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule clinical pharmacology|Clinical Pharmacology]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule clinical studies|Clinical Studies]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule patient counseling information|Patient Counseling Information]]'''
'''| [[PROZAC (fluoxetine hydrochloride) capsule labels and packages|Labels and Packages]]'''


==PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release==
|indication=




'''  [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release indications and usage|Indications and Usage]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release dosage and administration|Dosage and Administration]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release contraindications|Contraindications]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release warnings and precautions|Warnings and Precautions]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release adverse reactions|Adverse Reactions]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release drug interactions|Drug Interactions]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release use in specific populations|Use in Specific Populations]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release overdosage|Overdosage]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release description|Description]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release clinical pharmacology|Clinical Pharmacology]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release clinical studies|Clinical Studies]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release patient counseling information|Patient Counseling Information]]'''
'''| [[PROZAC WEEKLY (fluoxetine hydrochloride) capsule, delayed release labels and packages|Labels and Packages]]'''


==Mechanism of Action==
|hasBlackBoxWarning=


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = FLUOXETINE (FLUOXETINE HYDROCHLORIDE) SOLUTION [MORTON GROVE PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=142f9b27-65a7-4add-bdcc-2468695fedff | publisher =  | date =  | accessdate = }}</ref>
Yes
<ref>{{Cite web  | last =  | first =  | title = PROZAC (FLUOXETINE HYDROCHLORIDE) CAPSULE [DISTA PRODUCTS COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c88f33ed-6dfb-4c5e-bc01-d8e36dd97299 | publisher =  | date =  | accessdate = }}</ref><ref>{{Cite web  | last =  | first =  | title = PROZAC WEEKLY (FLUOXETINE HYDROCHLORIDE) CAPSULE, DELAYED RELEASE [ELI LILLY AND COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f356c1b-96bd-4ef1-960c-91cf4905e6b1 | publisher =  | date =  | accessdate =  }}</ref>


==Dosing and Administration==
|adverseReactions=
'''Major Depressive Disorder'''<br>
Adult — In controlled trials used to support the efficacy of fluoxetine, patients were administered morning doses ranging from 20 to 80 mg/day.
Studies comparing fluoxetine 20, 40, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a satisfactory response in major
depressive disorder in most cases. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose.
A dose increase may be considered after several weeks if insufficient clinical improvement is observed. Doses above 20 mg/day may be
administered on a once-a-day (morning) or BID schedule (i.e., morning and noon) and should not exceed a maximum dose of 80 mg/day.
<br>
<br>
'''Obsessive-Compulsive Disorder'''<br>
Adult — In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of OCD, patients were administered fixed daily
doses of 20, 40, or 60 mg of fluoxetine or placebo. In 1 of these studies, no dose-response relationship for effectiveness was
demonstrated. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose. Since there was a suggestion of
a possible dose-response relationship for effectiveness in the second study, a dose increase may be considered after several weeks if insufficient
clinical improvement is observed. The full therapeutic effect may be delayed until 5 weeks of treatment or longer.
Doses above 20 mg/day may be administered on a once-a-day (i.e., morning) or BID schedule (i.e., morning and noon). A dose range of 20 to
60 mg/day is recommended; however, doses of up to 80 mg/day have been well tolerated in open studies of OCD. The maximum fluoxetine dose
should not exceed 80 mg/day.
<br>
<br>
'''Bulimia Nervosa'''<br>
In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of bulimia nervosa, patients were administered fixed daily
fluoxetine doses of 20 or 60 mg, or placebo. Only the 60-mg dose was statistically significantly superior to placebo in
reducing the frequency of binge-eating and vomiting. Consequently, the recommended dose is 60 mg/day, administered in the morning. For some
patients it may be advisable to titrate up to this target dose over several days. Fluoxetine doses above 60 mg/day have not been systematically
studied in patients with bulimia.
<br>
<br>
'''Panic Disorder'''<br>
In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of panic disorder, patients were administered fluoxetine
doses in the range of 10 to 60 mg/day. Treatment should be initiated with a dose of 10 mg/day. After 1 week, the dose should
be increased to 20 mg/day. The most frequently administered dose in the 2 flexible-dose clinical trials was 20 mg/day.
<br>
<br>
For more detailed information on dosing please refer to [[Fluoxetine instructions for administration| Instructions for administration]]
<br>
<br>
----
<br>
<font size="4">
[[{{PAGENAME}}#FDA Package Insert Resources|FDA Package Insert Resources]]
<br></font size><small>Indications, Contraindications, Side Effects, Drug Interactions, etc.</small><font size="4"><br>
<br>
[http://www.pace-med-apps.com/gfrcalc.htm Calculate Creatine Clearance]
<br></font size><small>On line calculator of your patients Cr Cl by a variety of formulas.</small><font size="4"><br>
<br>
[http://home.earthlink.net/~sensei11/convert.htm Convert pounds to Kilograms]
<br></font size><small>On line calculator of your patients weight in pounds to Kg for dosing estimates.</small><font size="4"><br>
<br> [[{{PAGENAME}}#Publication Resources|Publication Resources]]
<br></font size><small>Recent articles, WikiDoc State of the Art Review, Textbook Information</small><font size="4"><br>
<br>
[[{{PAGENAME}}#Trial Resources|Trial Resources]]
<br></font size><small>Ongoing Trials, Trial Results</small><font size="4"><br>
<br>
[[{{PAGENAME}}#Guidelines & Evidence Based Medicine Resources|Guidelines & Evidence Based Medicine Resources]]
<br></font size><small>US National Guidelines, Cochrane Collaboration, etc.</small><font size="4"><br>
<br>
[[{{PAGENAME}}#Media Resources|Media Resources]]
<br></font size><small>Slides, Video, Images, MP3, Podcasts, etc.</small><font size="4"><br><br>
[[{{PAGENAME}}#Patient Resources|Patient Resources]]
<br></font size><small>Discussion Groups, Handouts, Blogs, News, etc.</small><font size="4"><br>
<br>
[[{{PAGENAME}}#International Resources|International Resources]]
<br></font size><small>en Español</small><font size="4"><br>
<br>
----
<br>
<br>
<br>
<br>


==FDA Package Insert Resources==
[[{{PAGENAME}} indications|Indications]]
<br>
<br>
[[{{PAGENAME}} contraindications|Contraindications]]
<br>
<br>
[[{{PAGENAME}} side effects|Side Effects]]
<br>
<br>
[[{{PAGENAME}} drug interactions|Drug Interactions]]
<br>
<br>
[[{{PAGENAME}} precautions|Precautions]]
<br>
<br>
[[{{PAGENAME}} overdose|Overdose]]
<br>
<br>
[[{{PAGENAME}} instructions for administration|Instructions for Administration]]
<br>
<br>
[[{{PAGENAME}} how supplied|How Supplied]]
<br>
<br>
[[{{PAGENAME}} pharmacokinetics and molecular data|Pharmacokinetics and Molecular Data]]
<br>
<br>
[http://www.fda.gov/medwatch/SAFETY/2004/aug_PI/Prozac_PI.pdf FDA label]
<br>
<br>
[http://google2.fda.gov/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&x=0&y=0&client=FDA&site=FDA&lr=&proxystylesheet=FDA&output=xml_no_dtd&getfields=* FDA on {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>


==Publication Resources==
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Most Recent Articles on {{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}%20AND%20systematic%5Bsb%5D  Review Articles on {{PAGENAME}}]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28%28N+Engl+J+Med%5Bta%5D%29+OR+%28Lancet%5Bta%5D%29+OR+%28BMJ%5Bta%5D%29%29 Articles on {{PAGENAME}} in N Eng J Med, Lancet, BMJ]
<br>
<br>
[[WikiDoc state of the art review on {{PAGENAME}}|WikiDoc State of the Art Review]]
<br>
<br>
[http://books.google.com/books?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=gp Textbook Information on {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>


==Trial Resources==
<!--Black Box Warning-->
[http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Ongoing Trials with {{PAGENAME}} at Clinical Trials.gov]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+AND+%28randomized+controlled+trial%5BPublication+Type%5D+OR+%28randomized%5BTitle%2FAbstract%5D+AND+controlled%5BTitle%2FAbstract%5D+AND+trial%5BTitle%2FAbstract%5D%29%29 Trial Results with {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>


|blackBoxWarningTitle=
Title


==Guidelines & Evidence Based Medicine Resources==
|blackBoxWarningBody=
[http://www.guideline.gov/search/searchresults.aspx?Type=3&txtSearch={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&num=20 US National Guidelines Clearinghouse on {{PAGENAME}}]
<i><span style="color:#FF0000;">ConditionName: </span></i>
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cochrane Database Syst Rev[ta])}} Cochrane Collaboration on {{PAGENAME}}]
<br>
<br>
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term={{urlencode:({{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}) AND (Cost effectiveness)}} Cost Effectiveness of {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
==Media Resources==
[http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+ppt&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a Powerpoint Slides on {{PAGENAME}}]
<br>
<br>
[http://images.google.com/images?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wi Images of {{PAGENAME}}]
<br>
<br>
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&hs=hPo&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+podcasts+OR+MP3&btnG=Search Podcasts & MP3s on {{PAGENAME}}]
<br>
<br>
[http://video.google.com/videosearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&um=1&sa=N&tab=fv# Videos on {{PAGENAME}}]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>


* Content


==Patient Resources==
<!--Adult Indications and Dosage-->
[[{{PAGENAME}} (patient information)|Patient Information from National Library of Medicine]]
<br>
<br>
[http://www.google.com/search?hl=en&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:for_patients&cx=disease_for_patients&sa=N&oi=cooptsr&resnum=0&ct=col3&cd=1  Patient Resources on {{PAGENAME}}]
<br>
<br>
[http://groups.google.com/groups/search?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search Discussion Groups on {{PAGENAME}}]
<br>
<br>
[http://www.google.com/search?hl=en&client=firefox-a&rls=org.mozilla:en-US:official&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+more:patient_handouts&cx=disease_for_health_professionals&sa=N&oi=coopctx&resnum=0&ct=col1&cd=3 Patient Handouts on {{PAGENAME}}]
<br>
<br>
[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]
<br>
<br>
[http://news.google.com/news?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wn {{PAGENAME}} in the News]
<br>
<br>
[http://finance.google.com/finance?ie=UTF-8&oe=utf-8&q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&qt_s=Search&sa=N&tab=te {{PAGENAME}} in the Marketplace]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>


==International Resources==
<!--FDA-Labeled Indications and Dosage (Adult)-->
[http://www.google.com/search?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}+en+espanol&ie=utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a {{PAGENAME}} en Español]
<br>
<br>
</font size><small>[[{{PAGENAME}}#Dosing and Administration|Return to top]]</small><font size="4">
<br>
<br>
</font size>
----


==References==
|fdaLIADAdult=


{{Reflist|2}}
=====Condition1=====


{{Antimigraine preparations}}
* Dosing Information
[[Category:Drugs]]


:* Dosage


{{FDA}}
=====Condition2=====


[[Category:Drugs]]
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
* Condition1
 
<!--Warnings-->
 
|warnings=
 
* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category'''
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
 
* Intravenous
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
 
|drugBox=
 
 
 
<!--Mechanism of Action-->
 
|mechAction=
 
*
 
<!--Structure-->
 
|structure=
 
*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
 
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
 
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
 
|clinicalStudies=
 
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
 
|howSupplied=
 
*
 
<!--Patient Counseling Information-->
 
|fdaPatientInfo=
 
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
 
|alcohol=
 
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
 
|brandNames=
 
* ®<ref>{{Cite web | title =  | url =  }}</ref>
 
<!--Look-Alike Drug Names-->
 
|lookAlike=
 
* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
 
<!--Drug Shortage Status-->
 
|drugShortage=
}}
 
<!--Pill Image-->
 
{{PillImage
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|drugName=
|NDC=
|drugAuthor=
|ingredients=
|pillImprint=
|dosageValue=
|dosageUnit=
|pillColor=
|pillShape=
|pillSize=
|pillScore=
}}
 
<!--Label Display Image-->
 
{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}
 
{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}
 
<!--Category-->
 
[[Category:Drug]]

Revision as of 22:40, 4 October 2014

Fluoxetine
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content

Overview

Fluoxetine is a that is FDA approved for the {{{indicationType}}} of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Fluoxetine in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Fluoxetine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Fluoxetine in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Fluoxetine in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Fluoxetine in pediatric patients.

Contraindications

  • Condition1

Warnings

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content
  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Fluoxetine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Fluoxetine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Fluoxetine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Fluoxetine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Fluoxetine with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Fluoxetine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Fluoxetine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Fluoxetine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Fluoxetine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Fluoxetine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Fluoxetine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Fluoxetine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Fluoxetine in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Fluoxetine in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Fluoxetine in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Fluoxetine in the drug label.

Pharmacology

There is limited information regarding Fluoxetine Pharmacology in the drug label.

Mechanism of Action

Structure

File:Fluoxetine01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Fluoxetine in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Fluoxetine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Fluoxetine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Fluoxetine in the drug label.

How Supplied

Storage

There is limited information regarding Fluoxetine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Fluoxetine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Fluoxetine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Fluoxetine in the drug label.

Precautions with Alcohol

  • Alcohol-Fluoxetine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. Empty citation (help)
  2. "http://www.ismp.org". External link in |title= (help)


{{#subobject:

 |Page Name=Fluoxetine
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject:

 |Label Page=Fluoxetine
 |Label Name=Fluoxetine11.png

}}


{{#subobject:

 |Label Page=Fluoxetine
 |Label Name=Fluoxetine11.png

}}